Skip to main content
Clinical Trials/NCT06044064
NCT06044064
Not yet recruiting
Not Applicable

"Effect of Screening Using Imaging (CT/ EUS) on Early Detection of Pancreatic Ductal Adenocarcinoma (PDAC) in Patients With New Onset Diabetes (NOD)" - A Prospective Pilot Observational Study

Asian Institute of Gastroenterology, India0 sites100 target enrollmentDecember 1, 2023

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Pancreatic Ductal Adenocarcinoma (PDAC)
Sponsor
Asian Institute of Gastroenterology, India
Enrollment
100
Primary Endpoint
Incidence of PDAC at 3 years
Status
Not yet recruiting
Last Updated
2 years ago

Overview

Brief Summary

To assess whether EUS (Endoscopic Ultrasound) can serve as a valuable diagnostic tool for identifying PDAC at an early stage in individuals who have recently been diagnosed with diabetes.

Purpose: To improve the rates of early detection of pancreatic cancer.

Pancreatic ductal adenocarcinoma (PDAC) is a type of cancer that starts in the pancreas, a gland located in your abdomen. It happens when some cells in the pancreas start growing abnormally and form a cancer.

Registry
clinicaltrials.gov
Start Date
December 1, 2023
End Date
September 1, 2027
Last Updated
2 years ago
Study Type
Observational
Sex
All

Investigators

Sponsor
Asian Institute of Gastroenterology, India
Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Age \> 50 years
  • Patients diagnosed with diabetes based on FBS/ PPBS/ HbA1C
  • Presence of atleast 1 FBS parameter measured in the past 6-18 months which was not \> 125 mg/dl
  • END-PDAC score \> 2

Exclusion Criteria

  • Known or newly detected chronic pancreatitis
  • Past history of pancreatic cancer
  • History of steroid use
  • Contraindications for EUS

Outcomes

Primary Outcomes

Incidence of PDAC at 3 years

Time Frame: 3yrs

Secondary Outcomes

  • • Incidence of PDAC at baseline • Incidence of resectable PDAC at baseline • Incidence of resectable PDAC at 3 years(baseline and 3yrs)

Similar Trials